Hasil Pencarian - Paula Curtis

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    1501 Long-term safety of belimumab among adult patients with systemic lupus erythematosus (SLE): pooled data from three open-label extension studies over 11+ years

    1501 Long-term safety of belimumab among adult patients with systemic lupus erythematosus (SLE): pooled data from three open-label extension studies over 11+ years oleh Munther Khamashta, Ricard Cervera, Daniel J Wallace, Maria G Tektonidou, Tatsuya Atsumi, Paula Curtis, Christine Henning, Aneela N Mian

    Diterbitkan 2024-05-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

    Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea oleh Damon Bass, Regina Kurrasch, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

    The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study oleh Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

    Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years oleh Damon Bass, Regina Kurrasch, Yin Su, Jie Zheng, Yang Li, Guochun Wang, Fengchun Zhang, David A Roth, Jieruo Gu, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik, Mingjun Wang, Xingfu Li

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: